Recurrent severe cutaneous reaction to fluoroquinolones and rifampicin in a human immunodeficiency virus-positive patient with disseminated tuberculosis: A rare case report
Abstract
Abstract: We report a 47-year-old human immunodeficiency virus-positive male with disseminated tuberculosis who developed recurrent maculopapular eruptions with mucosal involvement following exposure to multiple drugs, including diclofenac, rifampicin, and fluoroquinolones. Sequential drug rechallenge strongly implicated fluoroquinolones and rifampicin. He was successfully managed with systemic corticosteroids, intravenous immunoglobulin, and careful sequential reintroduction of nonculprit anti-tubercular therapy drugs. This case highlights the importance of drug reintroduction and cautious use of fluoroquinolones and rifampicin in immunocompromised patients.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.